诺和诺德(NVO.US)大涨超5%

Core Viewpoint - Novo Nordisk (NVO.US) shares rose over 5% to $60.3 following the approval of the 7.2 mg high-dose obesity treatment Wegovy in the UK [1] Group 1: Company Developments - The approval of Wegovy 7.2 mg for obesity treatment in the UK is a significant milestone for Novo Nordisk [1] - Wegovy oral tablets generated 3,071 prescriptions in the first four days after their launch in the United States, according to IQVIA data shared by analysts [1]